SEARCH

SEARCH BY CITATION

References

  • Beers, S.A., Chan, C.H., James, S., French, R.R., Attfield, K.E., Brennan, C.M., Ahuja, A., Shlomchik, M.J., Cragg, M.S. & Glennie, M.J. (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood, 112, 41704177.
  • Beers, S.A., French, R.R., Chan, C.H., Lim, S.H., Jarrett, T.C., Mora Vidal, R., Wijayaweera, S.S., Dixon, S.V., Kim, H.J., Cox, K.L., Kerr, J.P., Johnston, D.A., Johnson, P.W., Verbeek, S., Glennie, M.J. & Cragg, M.S. (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 115, 51915201.
  • Bellosillo, B., Villamor, N., Lopez-Guillermo, A., Marce, S., Esteve, J., Campo, E., Colomer, D. & Montserrat, E. (2001) Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 98, 27712777.
  • Bornstein, G.G., Queva, C., Tabrizi, M., van Abbema, A., Chavez, C., Wang, P., Foord, O., Ahluwalia, K., Laing, N., Raja, S., Wen, S., Green, L.L., Yang, X., Webster, C., Stewart, R. & Blakey, D. (2010) Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs, 28, 561574.
  • Bowles, J.A., Wang, S.Y., Link, B.K., Allan, B., Beuerlein, G., Campbell, M.A., Marquis, D., Ondek, B., Wooldridge, J.E., Smith, B.J., Breitmeyer, J.B. & Weiner, G.J. (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood, 108, 26482654.
  • Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., Pearson, M., Waselenko, J.K., Ling, G., Grever, M.R., Grillo-Lopez, A.J., Rosenberg, J., Kunkel, L. & Flinn, I.W. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology, 19, 21532164.
  • Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 614.
  • Cardarelli, P.M., Quinn, M., Buckman, D., Fang, Y., Colcher, D., King, D.J., Bebbington, C. & Yarranton, G. (2002) Binding to CD20 by anti-B1 antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunology, Immunotherapy, 51, 1524.
  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754758.
  • Chan, H.T., Hughes, D., French, R.R., Tutt, A.L., Walshe, C.A., Teeling, J.L., Glennie, M.J. & Cragg, M.S. (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Research, 63, 54805489.
  • Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., Hoelzer, D., Mitrou, P.S. & Weidmann, E. (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica, 87, 3343.
  • Cragg, M.S., Morgan, S.M., Chan, H.T., Morgan, B.P., Filatov, A.V., Johnson, P.W., French, R.R. & Glennie, M.J. (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 101, 10451052.
  • Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G.B., Wagner, H. & Peschel, C. (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood, 95, 9991006.
  • Decker, T., Hipp, S., Ringshausen, I., Bogner, C., Oelsner, M., Schneller, F. & Peschel, C. (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood, 101, 278285.
  • Farag, S.S., Flinn, I.W., Modali, R., Lehman, T.A., Young, D. & Byrd, J.C. (2004) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood, 103, 14721474.
  • Ferrara, C., Brunker, P., Suter, T., Moser, S., Puntener, U. & Umana, P. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnology and bioengineering, 93, 851861.
  • Glennie, M.J., French, R.R., Cragg, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 44, 38233837.
  • Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. & Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 39003908.
  • Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. & Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 98, 33833389.
  • Goldenberg, D.M., Rossi, E.A., Stein, R., Cardillo, T.M., Czuczman, M.S., Hernandez-Ilizaliturri, F.J., Hansen, H.J. & Chang, C.H. (2009) Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood, 113, 10621070.
  • Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008b) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 54465456.
  • Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphotic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 11641174.
  • Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C. & Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 13261331.
  • Ivanov, A., Beers, S.A., Walshe, C.A., Honeychurch, J., Alduaij, W., Cox, K.L., Potter, K.N., Murray, S., Chan, C.H., Klymenko, T., Erenpreisa, J., Glennie, M.J., Illidge, T.M. & Cragg, M.S. (2009) Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. Journal of Clinical Investigation, 119, 21432159.
  • Jahrsdorfer, B., Hartmann, G., Racila, E., Jackson, W., Muhlenhoff, L., Meinhardt, G., Endres, S., Link, B.K., Krieg, A.M. & Weiner, G.J. (2001) CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. Journal of Leukocyte Biology, 69, 8188.
  • Keating, M.J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M.A., Lynn, A. & Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 40794088.
  • Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J.P., Lozanski, G., Ramanunni, A., Smith, L.L., Blum, W., Andritsos, L., Wang, D.S., Lehman, A., Chen, C.S., Johnson, A.J., Marcucci, G., Lee, R.J., Lee, L.J., Tridandapani, S., Muthusamy, N. & Byrd, J.C. (2008) Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 112, 51805189.
  • Lefebvre, M.L., Krause, S.W., Salcedo, M. & Nardin, A. (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. Journal of Immunotherapy, 29, 388397.
  • Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J. & Cragg, M.S. (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 95, 135143.
  • Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K. & Hatake, K. (2009) An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clinical Cancer Research, 15, 36243632.
  • Molina, A. (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annual Review of Medicine, 59, 237250.
  • Morschhauser, F., Cartron, G., Lamy, T., Milpied, N.-J., Thieblemont, C., Tilly, H., Weisser, M., Birkett, J. & Salles, G.A. (2009) Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 114, (ASH Annual Meeting Abstracts) 884.
  • Mössner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schuell, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J.S., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 43934402.
  • O’Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., Lerner, S. & Keating, M.J. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 21652170.
  • Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A.J., Baeuerle, P.A. & Prang, N.S. (2006) High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Molecular Immunology, 43, 11831193.
  • Rassenti, L.Z., Jain, S., Keating, M.J., Wierda, W.G., Grever, M.R., Byrd, J.C., Kay, N.E., Brown, J.R., Gribben, J.G., Neuberg, D.S., He, F., Greaves, A.W., Rai, K.R. & Kipps, T.J. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 112, 19231930.
  • de Romeuf, C., Dutertre, C.A., Le Garff-Tavernier, M., Fournier, N., Gaucher, C., Glacet, A., Jorieux, S., Bihoreau, N., Behrens, C.K., Beliard, R., Vieillard, V., Cazin, B., Bourel, D., Prost, J.F., Teillaud, J.L. & Merle-Beral, H. (2008) Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. British Journal Haematology, 140, 635643.
  • Stacchini, A., Aragno, M., Vallario, A., Alfarano, A., Circosta, P., Gottardi, D., Faldella, A., Rege_Cambrin, G., Thunberg, U., Nilsson, K. & Caligaris_Cappio, F. (1999) MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Research, 23, 127136.
  • Stanglmaier, M., Reis, S. & Hallek, M. (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology, 83, 634645.
  • Tam, C.S., Otero-Palacios, J., Abruzzo, L.V., Jorgensen, J.L., Ferrajoli, A., Wierda, W.G., Lerner, S., O’Brien, S. & Keating, M.J. (2008) Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. British Journal Haematology, 141, 3640.
  • Taylor, R.P. & Lindorfer, M.A. (2008) Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Current Opinion in Immunology, 20, 444449.
  • Veldurthy, A., Patz, M., Hagist, S., Pallasch, C.P., Wendtner, C.M., Hallek, M. & Krause, G. (2008) The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood, 112, 14431452.
  • Voso, M.T., Pantel, G., Rutella, S., Weis, M., D’Alo, F., Urbano, R., Leone, G., Haas, R. & Hohaus, S. (2002) Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica, 87, 918925.
  • Weiner, G.J. & Hartmann, G. (2003) Methods for Enhancing Antibody-Induced Cell Lysis and Treating Cancer. Patent Application Publication, Alexandria, VA, USA.
  • Weitzman, J., Betancur, M., Boissel, L., Rabinowitz, A.P., Klein, A. & Klingemann, H. (2009) Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leukaemia and Lymphoma, 50, 13611368.
  • Zent, C.S., Secreto, C.R., LaPlant, B.R., Bone, N.D., Call, T.G., Shanafelt, T.D., Jelinek, D.F., Tschumper, R.C. & Kay, N.E. (2008) Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leukemia Research, 32, 18491856.